Viewing Study NCT05713292


Ignite Creation Date: 2025-12-24 @ 3:30 PM
Ignite Modification Date: 2026-01-06 @ 6:22 AM
Study NCT ID: NCT05713292
Status: COMPLETED
Last Update Posted: 2024-07-03
First Post: 2023-01-01
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Pirfenidone in Adult Hospitalized Patients With COVID-19
Sponsor: Capital Medical University
Organization:

Study Overview

Official Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pirfenidone in Adult Hospitalized Patients With COVID-19.
Status: COMPLETED
Status Verified Date: 2024-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This center intends to conduct a multicenter, randomized, placebo-controlled study to evaluate the effectiveness and safety of Nintedanib ethanesulfonate soft capsule in the treatment of pulmonary fibrosis in patients with moderate to severe COVID-19.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: